Kinnate Biopharma, Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Kinnate Biopharma, Inc. - overview
Established
2018
Location
San Diego, CA, US
Primary Industry
Biotechnology
About
Based in California, US, and founded in 2018 by CEO Nima Farzan, Kinnate Biopharma, Inc. operates as a clinical-stage precision oncology company providing cancer treatments. In February 2024, XOMA Corporation agreed to acquire Kinnate Biopharma, Inc. Kinnate Biopharma, Inc.
developed a pipeline of small molecule drug candidates through its Kinnate Discovery Engine. It offers two main clinical programs targeting solid tumors with RAF, NRAS, and FGFR-driven alterations. The company's lead product candidates include exarafenib, an investigational pan-RAF inhibitor for cancers with BRAF and NRAS mutations, and KIN-3248, an investigational FGFR inhibitor targeting cancers with FGFR2 and FGFR3 alterations. In addition, the firm provides early-stage programs including c-MET inhibitor designed to target resistant variants and a brain-penetrant CDK4 selective inhibitor program.
Current Investors
OrbiMed Advisors, Nextech, Foresite Capital
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Oncology/Cancer Treatment, Pharmaceutical Research & Development
Website
www.kinnate.com
Verticals
HealthTech
Company Stage
Mature
Total Amount Raised
Subscriber access only
Kinnate Biopharma, Inc. - financials
| Fiscal Year Ended | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 |
|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - |
| EBITDA (USD) | - | - | (35,913,000) | - | - | - |
| Operating Income (USD) | - | - | (36,001,000) | - | - | - |
| Operating Margin | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - |
| NET Income (USD) | 7,600,000 | 12,000,000 | (35,761,000) | - | - | - |
| % Net Margin | - | - | - | - | - | - |
Kinnate Biopharma, Inc. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.